Evidence map›Paper›PMID 42707883›Full record

ArticleJournal of gastrointestinal oncology2026

Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis.

Jinchuan Xi, Zhihan Li, Youqiang Liu, Zheng Li, Wenbo Niu, Lianmei Zhao, Bin Yu, Guiying Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinchuan XiThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhihan LiThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Youqiang LiuThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zheng LiThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Wenbo NiuThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Lianmei ZhaoResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Bin YuThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Guiying WangThe Second Department of Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Emerging evidence indicates that the lncRNA Methods: The action network of artemisinin was analyzed using network pharmacology. Stable Results: Artemisinin was predicted to target 96 proteins associated with CRC, including Conclusions: Artemisinin promoted proteasome-mediated degradation of HIF-1α protein and inhibited CRC progression, potentially through the

Indexed as

Artemisinincolorectal cancer (CRC)FAM83A-AS1glycolysisHIF-1α

Identifiers

PMID42707883
PMCPMC13548359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.